Search research articles
Contact Us
Filters
Showing results (171-180 of 197) with videos related to
Page
of 20
Sort By:
The Lancet Regional Health. Western Pacific
|
July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancer
Yuankai Shi, Gongyan Chen, Xiang Wang, et al.
JMIR Cancer
|
June 5, 2024
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study
Di Zheng, Yanhong Shang, Jian Ni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2024
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Yuankai Shi, Jianhua Chen, Runxiang Yang, et al.
Frontiers in Medicine
|
October 21, 2022
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study
Weineng Feng, Yufeng Wang, Fengming Ran, et al.
The Lancet. Respiratory Medicine
|
September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
The Lancet Regional Health. Western Pacific
|
April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
JTO Clinical and Research Reports
|
June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial
Nicolas Girard, Jonathan Goldman, Shun Lu, et al.
Signal Transduction and Targeted Therapy
|
January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
Yuankai Shi, Jian Fang, Xuezhi Hao, et al.
Clinical and Translational Medicine
|
December 14, 2023
Association of lung diseases with coronavirus disease 2019 in cancer patients receiving immune checkpoint inhibitors: A multicenter study during national Omicron outbreak in China
Yanlin Li, Tongfei Wang, Yamin Zhang, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 197) with videos related to
Sort By:
Page
of 20
The Lancet Regional Health. Western Pacific
|
July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancer
Yuankai Shi, Gongyan Chen, Xiang Wang, et al.
JMIR Cancer
|
June 5, 2024
Telehealth With Comprehensive Live-Fed Real-World Data as a Patient Care Platform for Lung Cancer: Implementation and Evaluation Study
Di Zheng, Yanhong Shang, Jian Ni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 27, 2024
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)
Yuankai Shi, Jianhua Chen, Runxiang Yang, et al.
Frontiers in Medicine
|
October 21, 2022
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study
Weineng Feng, Yufeng Wang, Fengming Ran, et al.
The Lancet. Respiratory Medicine
|
September 13, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
The Lancet Regional Health. Western Pacific
|
April 6, 2026
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic <i>MET</i> exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study
Yongfeng Yu, Qisen Guo, Yongchang Zhang, et al.
JTO Clinical and Research Reports
|
June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial
Nicolas Girard, Jonathan Goldman, Shun Lu, et al.
Signal Transduction and Targeted Therapy
|
January 28, 2022
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial
Yuankai Shi, Jian Fang, Xuezhi Hao, et al.
Clinical and Translational Medicine
|
December 14, 2023
Association of lung diseases with coronavirus disease 2019 in cancer patients receiving immune checkpoint inhibitors: A multicenter study during national Omicron outbreak in China
Yanlin Li, Tongfei Wang, Yamin Zhang, et al.
BMC Medicine
|
April 29, 2023
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
Xingsheng Hu, Shucai Zhang, Zhiyong Ma, et al.
Page
of 20